To conduct a comprehensive clinical evaluation of Compound Jinqiancao Granules for the treatment of urinary calculi(UC) with dampness-heat pouring down syndrome.Methods:A multidisciplinary approach integrating clinical epidemiology，evidence-based medicine，health technology assessment，and questionnaire surveys was employed to evaluate the safety，efficacy，economic value，and other relevant aspects of Compound Jinqiancao Granules for the treatment of UC.A multi-criteria decision analysis framework was applied for comprehensive clinical assessment.Results:The evaluation included spontaneous reporting system(SRS) data analysis，post-marketing randomized controlled trials(RCTs)，and meta-analyses，indicating sufficient safety evidence with minimal known risks，resulting in a B-grade safety rating.This product，when combined with conventional Western medicine，improved the cure rate and accelerated stone expulsion in both postoperative and non-surgical treatment of UC，with an A-grade efficacy rating.Cost-effectiveness analysis showed an incremental cost-effectiveness ratio(ICER) of 2 270 CNY，with stable sensitivity analysis results.The product's price was moderate compared to similar treatments，leading to a B-grade economic evaluation.As a patented product，the manufacturer emphasizes service systems and industrial innovation，receiving a B-grade innovation rating.The product demonstrated good suitability for both healthcare providers and patients，earning a B-grade suitability rating.With a relatively low price and good affordability 7.32% for urban residents and 19.44% for rural residents—the product benefits from abundant medicinal resources，leading to an A-grade accessibility rating.Designed specifically for the dampness-heat pouring down syndrome，the formulation has accumulated post-marketing human experience exceeding 2 000 cases，receiving a B-grade TCM characteristics rating.Conclusion:The comprehensive clinical evaluation of Compound Jinqiancao Granules for UC with dampness-heat pouring down syndrome is B-grade.